On Feb. 26, 2004, the U.S. Food and Drug Administration (FDA) announced it had approved the first antiangiogenic drug for cancer, Avastin developed by Genentech.

This was the first biologic medicine (not a chemotherapy) approved by the FDA designed to inhibit angiogenesis.